Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases.

@article{Ridley2010IntroductionOE,
  title={Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases.},
  author={David B. Ridley and Alfonso Calles S{\'a}nchez},
  journal={Lancet},
  year={2010},
  volume={376 9744},
  pages={922-7}
}
Every year 1 billion people worldwide are affected by traditionally neglected diseases, such as malaria, tuberculosis, leishmaniasis, and lymphatic filariasis, which impose tremendous public health burdens. Governments, foundations, and drug manufacturers have, however, started to support development of new treatments. European Union Member States have been leaders in implementing so-called push mechanisms (payment for drug development) and pull funding (reward for output), such as the advance… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.
5 Citations
27 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 27 references

14 Paragraph 1434 of the Pharmaceutical Inquiry Final Report

  • European Commission
  • 2009

European Commission

  • European Commission
  • 2009

Implementing paediatric extensions to SPCs: marketing authorization in 'all Member States

  • Calles, A Sánchez
  • Oxford University J Intellect Prop Law Pract
  • 2009

In defense of priority review vouchers

  • J Sonderhom
  • Bioethics
  • 2009

Neglected tropical diseases: hidden successes, emerging opportunities

  • Geneva: World Health Organization
  • 2009

Priority review vouchers to encourage innovation for neglected diseases Prescribing cultures and pharmaceutical policy in the Asia‐Pacific

  • Hg Grabowski, Db Ridley, Jl Moe
  • Priority review vouchers to encourage innovation…
  • 2009

12 Annual report of the European Medicines Agency

  • 12 Annual report of the European Medicines Agency
  • 2008

Similar Papers

Loading similar papers…